Yusuke Ogitani
- Oncology top 1%
- Radiology, Nuclear Medicine and Imaging top 1%
- Pulmonary and Respiratory Medicine top 5%
- Molecular Biology
- Immunology
- Co-authors
- Toshinori AgatsumaMasataka OitateKatsunobu HagiharaHiroyuki NaitoChiaki IshiiYuki AbeJunko YamaguchiTakashi Nakada
- Topics
- HER2/EGFR in Cancer Research (13 papers)Monoclonal and Polyclonal Antibodies Research (12 papers)Cancer Treatment and Pharmacology (3 papers)
- Partner nations
- JapanGermanyUnited States
In The Last Decade
Yusuke Ogitani
15 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 59
- Oncology 2.0k
- Radiology, Nuclear Medicine and Imaging 1.2k
- Pulmonary and Respiratory Medicine 676
- Molecular Biology 396
- Immunology 137
Countries citing papers authored by Yusuke Ogitani
This map shows the geographic impact of Yusuke Ogitani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuke Ogitani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuke Ogitani more than expected).
Fields of papers citing papers by Yusuke Ogitani
This network shows the impact of papers produced by Yusuke Ogitani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuke Ogitani. The network helps show where Yusuke Ogitani may publish in the future.
Co-authorship network of co-authors of Yusuke Ogitani
This figure shows the co-authorship network connecting the top 25 collaborators of Yusuke Ogitani. A scholar is included among the top collaborators of Yusuke Ogitani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuke Ogitani. Yusuke Ogitani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 10 | |
| 3 | 24 | |
| 4 | 47 | |
| 5 | 202 | |
| 6 | Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation studybreakdown → | 362 |
| 7 | 4 | |
| 8 | 139 | |
| 9 | 4 | |
| 10 | 1 | |
| 11 | Bystander killing effect of | 479 |
| 12 | DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1breakdown → | 767 |
| 13 | 119 | |
| 14 | 35 | |
| 15 | 0 | |
| 16 | [Studies on the cytotoxic action of new restorative resins (in vitro) (author's transl)]. | 1 |
About Yusuke Ogitani
Yusuke Ogitani is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Biotechnology, having authored 16 papers that have together received 2.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (2.0k citations), Radiology, Nuclear Medicine and Imaging (1.2k citations) and Pulmonary and Respiratory Medicine (676 citations). Yusuke Ogitani has collaborated with scholars based in Japan, Germany and United States. Frequent co-authors include Toshinori Agatsuma, Masataka Oitate, Katsunobu Hagihara, Hiroyuki Naito, Chiaki Ishii, Yuki Abe, Junko Yamaguchi, Takashi Nakada, Hiromi Okamoto and Masako Soma. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.